Selective delivery of radionuclides to the type II transmembrane protein prostate-specific membrane antigen (PSMA) has been increasingly adopted as a potent concept for diagnostics and treatment of prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.